FUJI YAKUHIN ……..INNOVATOR
Approved in japan PMDA JUNE 28 2013
Xanthine oxidase inhibitor
FOR GOUT AND HYPERURICEMIA
Launched – 2013, Fuji YakuhinSanwa, Topiloric Uriadec
IUPAC Name: 4-(5-pyridin-4-yl-1H-1,2,4-triazol-3-yl)pyridine-2-carbonitrile
CAS Registry Number: 577778-58-6
4 – [5 – (pyridin-4 – yl)-1H-1, 2,4 – triazol-3 – yl] pyridine-2 – carbonitrile (1)
AC1NRB9T, Topiroxostat (JAN/INN), DB01685, D09786, FYX-051
C13H8N6 MF,248.2482 MW
A xanthine oxidase inhibitor used to treat gout and hyperuricemia.
PATENT EXP 3/12/22, US /EU/CN
FYX-051, TOPIROXOSTAT is a xanthine oxidase inhibitor. This agent was approved in Japan by Fuji Yakuhin and Sanwa for the treatment of gout and hyperuricemia in 2013 and launched at the same year. In 2009, the compound was licensed to Sanwa by Fuji Yakuhin in Japan for the codevelopment and commercialization of gout.
The number of patients with hyperuricemia in Japan is reported…
View original post 4,917 more words